Merck_PE - Reprint 9985050 - (Page 1) MAY 2008 THE BUSINESS MAGAZINE OF PHARMA Merck’s stock has been on a downward spiral over the last few months. And it’s no wonder: with the constant drumbeat of news and analysis over Vytorin, it’s been hard for investors to think about anything else. But if Merck can come back from Vioxx, it can engineer a comeback from Vytorin. How? Behind the scenes, the company is getting out in front by cherry picking the most promising compounds to pave its way toward future pro ts. Merck tendered three major late-stage How do you find and license the best drugs out there? If you’re Merck, you send scientists to go get ’em. Q&A with Barbara Yanni, Merck’s chief licensing officer. BY JOANNA BREITSTEIN, EXECUTIVE EDITOR (Scientific) Advantage Q+A deals last year alone: with NovaCardia for a heart failure drug; with Ariad for an oncology compound; and with Dynavax for a hepatitis B vaccine. What’s more, at press time the cholesterollowering drug Cordaptive—a could-be blockbuster—was before FDA awaiting approval. That makes Merck’s Phase III pipeline one of the strongest in the biz. The company is also locking up blue
Table of Contents Feed for the Digital Edition of Merck_PE - Reprint 9985050 Merck_PE - Reprint 9985050 Merck_PE - Reprint 9985050 - (Page 1) Merck_PE - Reprint 9985050 - (Page 2) Merck_PE - Reprint 9985050 - (Page 3) Merck_PE - Reprint 9985050 - (Page 4) Merck_PE - Reprint 9985050 - (Page 5) Merck_PE - Reprint 9985050 - (Page 6)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.